Both in Diagnostics
Celldex Therapeutics vs Myriad Genetics
Over the past year CLDX returned +25.5% and MYGN returned −6.8%; their daily moves had a correlation of 0.22.
CLDX +25.5% MYGN −6.8%Growth of $1, one year, split-adjusted
| Metric | CLDX | MYGN |
|---|---|---|
| Price | $29.93 | $6.02 |
| Market cap | $2.35B | $575.8M |
| Today | +0.74% | −0.33% |
| 1 month | −3.5% | +40.7% |
| 6 months | −13.0% | +46.5% |
| Year to date | +10.2% | −2.1% |
| 1 year | +20.9% | −26.4% |
| Revenue growth (YoY) | −97.0% | −10.5% |
| Gross margin | 100.0% | 66.6% |
| Net margin | −334104.5% | −22.7% |
| P/E (TTM) | — | — |
| Price / sales | 14,875.9× | 0.7× |
| Net cash | $717.6M | -$5.5M |
| Dividend yield | — | — |
| Volatility (60d) | 47.7% | 85.0% |
| Short % of float | 13.0% | 10.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).